Kidney stones, hard deposits of minerals and salts that form inside the kidneys, are among the most painful conditions, sending more than half a million people to the emergency room each year. An estimated one in 10 people will suffer from kidney stones at some point...
Encouraging the next generation of healthtech problem solvers is a key goal of Fogarty Innovation, and this summer it partnered with Stanford University’s inaugural two-week Surgical Technology & Entrepreneurship program for high school students to expose young...
Approximately 100,000 U.S. patients require a kidney transplant each year, with some waiting more than five years for a donor, and up to half of those dying in the interim. And even for the “lucky” ones who receive a transplant, there are still hurdles. In fact, one...
Ingrid Ellerbe has joined Diversity by Doing Healthtech (DxD), the health technology industry diversity initiative led by the Stanford Byers Center for Biodesign and Fogarty Innovation, as executive director. Ellerbe, who has spent the last 30 years helping...
The Medical Device Manufacturers Association (MDMA) has been a beacon during the COVID-19 crisis, working closely with the FDA and other key stakeholders to represent the needs of its members and bring innovative devices to patients swiftly but safely. That’s why...
At the most recent Stanford Biodesign’s “From the Innovator's Workbench” lecture series, the second of its 20th anniversary year, three high-powered women health tech leaders opened up about pivotal moments in their recent successes in bringing...
Foreword: The following is an abbreviated transcript from the latest in Fogarty Innovation’s series of casual, in-depth conversations aimed at discovering the person behind a transformative medtech leader. If you would like to see the entirety of the interview in a...
Clinical research is a core requirement of everything we do in the healthcare field—from accelerating treatments to developing the medical devices that save patients’ lives. Startups, in particular, recognize the value of having access to physicians and patients,...
Startup companies are all too familiar with the “valley of death,” which refers to the gap that lies between translating innovative technology from benchtop to actual clinical use and the ongoing need for funding. Accelerating technologies from idea to the...
Lauding recent additions and successes Despite the challenging environment presented by 2020, we are proud to report that companies-in-residence (CIRs) and graduates alike received funding, a testament to their fortitude and the value of the clinical needs they are...